Mirum Pharmaceuticals, Inc.

Quick facts

Marketed products

• Cholbam · Metabolic
• Livmarli · Other
• Livmarli Oral Product

Phase 3 pipeline

• CDCA Weight-Based Dose TID · Hepatology / Gastroenterology
  CDCA (chenodeoxycholic acid) is a bile acid that activates farnesoid X receptor (FXR) and TGR5 signaling to reduce bile acid synthesis and improve cholestasis.
• Cholic Acids · Gastroenterology / Metabolic Disorders
  Cholic acid is a primary bile acid that restores bile acid-dependent signaling pathways to improve cholestasis and fat malabsorption in patients with bile acid synthesis disorders.

Phase 2 pipeline

• High dose of MRM-3379
• Middle Dose of MRM-3379

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Mirum Pharmaceuticals, Inc. portfolio CI brief
• Mirum Pharmaceuticals, Inc. pipeline updates RSS